Rising Demand for Regenerative Medicine Opens Opportunities for Taiwanese Companies in Malaysia’s Stem Cell Market

As Malaysia faces a rapidly aging population, demand for regenerative medicine and stem cell therapies is on the rise, driving growth in the country's healthcare market and creating substantial opportunities within the region’s regenerative medicine sector. Against this backdrop, Malaysia is proactively implementing healthcare policies to accelerate the introduction of stem cell products, with hopes of fostering stronger technological collaboration with Taiwan, creating mutually beneficial opportunities for both healthcare industries.

The country’s aging population has amplified the need for regenerative therapies. According to TechNews, the accelerating aging trend has led to a sustained increase in demand for stem cell therapies. Regenerative medicine not only enhances the quality of life for patients but also serves as a crucial technology to address age-related diseases, easing pressure on Malaysia’s healthcare system. To support this growing need, the Malaysian government has introduced policies to advance the medical industry, providing a favorable regulatory environment for regenerative medicine products.

As Southeast Asia’s regenerative medicine market grows, Malaysia’s central position in the region is becoming more evident. Research from KPMG highlights that the regenerative medicine market in Southeast Asia is expected to continue expanding, positioning Malaysia as a key market for stem cell therapies and related products.

Past collaborations between Taiwan and Malaysia have already proven successful. In 2022, Taiwan’s China Medical University Hospital signed several memoranda of understanding with Malaysian partners, initiating close cooperation in stem cell technology and product exchanges. This partnership aims to deepen both countries' ties in the field of medical technology.

Since its establishment in 2002, CRYOCORD SDN BHD, the largest stem cell bank company in Southeast Asia, has focused on cell therapy research and the long-term cryopreservation of human stem cells and tissues. The company operates a cGMP (PIC/S) certified laboratory and has established designated partnerships with several Malaysian hospitals.

CRYOCORD is now seeking collaboration with Taiwanese medical institutions and companies, with a focus on advancing cell and gene therapy research, stem cell line preparation, and laboratory optimization. Through these partnerships, CRYOCORD aims to further advance regenerative medicine across Southeast Asia, offering patients more advanced treatment options.

● Also Want to Explore More Business Opportunities?
【Register for the 2024 Heathcare+ Expo Now to find the best partners! ▸】